ISIS Pharmaceuticals, Inc. Stock Nasdaq
Stocks
US4643301090
Biotechnology & Medical Research
| Market Cap | 8.93B 7.85B 7.33B 6.72B 12.58B 855B 12.89B 86.86B 33.97B 423B 33.53B 32.8B 1,463B | P/E 2026 * |
-15x | P/E 2027 * | -29.3x |
|---|---|---|---|---|---|
| Enterprise Value | 8.54B 7.5B 7B 6.42B 12.03B 818B 12.32B 83.01B 32.46B 405B 32.05B 31.35B 1,399B | EV / Sales 2026 * |
9.19x | EV / Sales 2027 * | 6.21x |
| Free-Float |
99.08% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: ISIS Pharmaceuticals, Inc.
| 1 day | +1.33% |
| Manager | Title | Age | Since |
|---|---|---|---|
D. Walke
IRC | Investor Relations Contact | 60 | 01/07/2012 |
Brett Monia
CEO | Chief Executive Officer | 64 | 01/01/2020 |
Elizabeth Hougen
DFI | Director of Finance/CFO | 64 | 01/05/2000 |
| Director | Title | Age | Since |
|---|---|---|---|
Joseph Klein
BRD | Director/Board Member | 64 | 13/12/2005 |
| Director/Board Member | 73 | 01/05/2002 | |
Brett Monia
BRD | Director/Board Member | 64 | 25/03/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.33% | +2.73% | - | - | 8.93B | |
| +0.45% | +6.53% | +0.59% | +14.33% | 48.95B | |
| +1.90% | +24.70% | +27.25% | +9.47% | 40.75B | |
| -1.60% | -1.15% | +388.84% | +603.70% | 38.46B | |
| -0.98% | +2.28% | +7.02% | +45.34% | 36.38B | |
| +1.47% | +5.82% | +5.76% | +43.52% | 28.45B | |
| -0.94% | +0.05% | - | - | 16.62B | |
| +2.44% | +10.76% | +30.59% | +129.56% | 16.33B | |
| -1.14% | +6.52% | -3.80% | -29.33% | 13.65B | |
| +0.35% | +4.17% | +4.24% | +10.07% | 13.56B | |
| Average | +0.33% | +5.79% | +57.56% | +103.33% | 28.13B | |
| Weighted average by Cap. | +0.27% | +6.92% | +71.96% | +122.81% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 929M 816M 762M 699M 1.31B 88.95B 1.34B 9.03B 3.53B 44.02B 3.49B 3.41B 152B | 1.4B 1.23B 1.15B 1.05B 1.97B 134B 2.02B 13.62B 5.33B 66.36B 5.26B 5.14B 229B |
| Net income | -602M -529M -493M -453M -848M -57.63B -869M -5.85B -2.29B -28.52B -2.26B -2.21B -98.59B | -332M -292M -273M -250M -468M -31.84B -480M -3.23B -1.26B -15.76B -1.25B -1.22B -54.47B |
| Net Debt | -396M -348M -324M -298M -557M -37.89B -571M -3.85B -1.5B -18.75B -1.49B -1.45B -64.81B | -241M -211M -197M -181M -339M -23.05B -347M -2.34B -915M -11.41B -904M -884M -39.44B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
